Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of 17 systematic review(s)/meta-analysis(es). ^[1-17]
• Hemoglobin A1c (HbA1c) Reduction: Lixisenatide combined with metformin resulted in an Incremental Net Monetary Benefit (INMB) of USD -1,713 compared to exenatide for HbA1c reduction. In a network meta-analysis involving 10 GLP (Glucagon-Like Peptide)-1RAs, specific reductions for lixisenatide were not detailed.
• Body Weight Reduction: Lixisenatide demonstrated weight reduction but was less effective compared to semaglutide and liraglutide.
• Glycemic Control in Asian Populations: A post hoc analysis revealed that lixisenatide improved HbA1c, fasting plasma glucose, and postprandial glucose, regardless of baseline BMI (Body Mass Index) in Asian individuals with type 2 diabetes inadequately controlled on basal insulin.
• Cardiovascular Outcomes: Lixisenatide did not show a significant reduction in cardiovascular events relative to other GLP-1RAs, with long-acting options like dulaglutide and semaglutide providing more substantial benefits.
• Adverse Events: Lixisenatide was associated with gastrointestinal adverse events, consistent with other GLP-1RAs, and showed no significant increase in hypoglycemia incidence compared to other GLP-1RAs.
• Serious Adverse Events: A network meta-analysis reported no significant difference in serious adverse events rates between lixisenatide, placebo, or other GLP-1RAs.
• Fracture Risk: Lixisenatide did not significantly raise fracture risk, positioning it as one of the safer options concerning fracture outcomes among anti-diabetic drugs.
• There is no population types or subgroups information available in the reviewed studies.